Signal
Novo’s CagriSema posts phase 3 diabetes win vs semaglutide; skye shares 52-week combo data
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-02-02 16:24 UTCUpdated 2026-02-02 20:04 UTC
rss
clinical_trialsdrug_developmentmetabolic_diseaseobesity
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
CagriSema’s blood sugar and weight reductions exceeded the company’s blockbuster Wegovy, yet the drug might still struggle to rival Lilly's Zepbound.
Entities
Novo NordiskSkye BioscienceCagriSemaWegovyZepboundsemaglutide
Score total
1.06
Momentum 24h
3
Posts
3
Origins
2
Source types
1
Duplicate ratio
0%
Why now
- Novo disclosed new phase 3 Type 2 diabetes results for CagriSema
- Skye released a 52-week update after failing to hit a primary endpoint
- Comparisons to Wegovy and Lilly’s Zepbound are central to current readouts
Why it matters
- Phase 3 diabetes data positions CagriSema against semaglutide/Wegovy benchmarks
- Missing a stated 25% weight-loss target may shape expectations for next-gen combos
- 52-week combo durability signals remain a key differentiator in obesity R&D
LLM analysis
Topic mix: lowPromo risk: lowSource quality: high
Recurring claims
- Novo Nordisk’s CagriSema outperformed semaglutide/Wegovy on blood sugar and weight measures in a phase 3 Type 2 diabetes study.
- CagriSema did not hit Novo Nordisk’s previously laid out 25% weight-loss mark for the asset.
- Skye Bioscience linked its investigational obesity drug combination to 22.3% total weight loss at week 52 while recovering from missing a primary endpoint.
How sources frame it
- BioPharma Dive: neutral
- Fierce Biotech: neutral
Cluster centers on obesity/metabolic drug development readouts: Novo Nordisk’s CagriSema phase 3 diabetes data and Skye Bioscience’s 52-week combo update.
All evidence
All evidence
Novo Nordisk’s GLP-1/amylin combo has topped blockbuster semaglutide in a phase 3 Type 2 diabetes trial, though CagriSema still didn't hit the 25% weight loss mark that the Dani...
Fierce Biotech · fiercebiotech.com · 2026-02-02 20:04 UTC
Novo combination obesity shot meets goal in diabetes trial
BioPharma Dive · biopharmadive.com · 2026-02-02 19:00 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- Fierce Biotech (1)
- BioPharma Dive (1)
Top origin domains (this list)
- fiercebiotech.com (1)
- biopharmadive.com (1)